The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF).
D ilated cardiomyopathy (DCMP) is the most common type of cardiomyopathy in children. It is a myocardial disorder characterized by left ventricular (LV) dysfunction and dilatation, and progresses to congestive heart failure. [1] Intracardiac thrombus (ICT) in patients with pediatric DCMP is a serious complication and potential source of important morbidity and mortality. ICT may result from various conditions including LV systolic dysfunction, low cardiac output, abnormal endocardial surface, dysrhythmia, and tendency towards thrombosis. [2] [3] [4] [5] [6] Prompt anticoagulant therapy is mandatory for DCMP patients who have rapidly worsening ventricular function history for ICT or history for embolic infarction to any part of the body. [7] The strongest indication for thrombolytic therapy includes either a life-or limb-threatening thrombotic event. Significant bleeding and thromboembolism are known complications of thrombolysis. Contraindications to thrombolytic therapy need to be considered, including active bleeding, an inability to maintain the platelet count >75.000/µL or fibrinogen >100 mg/dl, a major surgery or site of hemorrhage within 7 to 10 days, seizures within 48 hours, central nervous system surgery/ischemia/trauma/hemorrhage within 30 days, preterm infant <32 weeks, or uncontrolled hypertension. [8] Although the present study was designed as a retrospective study, we intended to attract attention to the follow-up of DCMP patients, the approach to the anticoagulant/antiaggregant therapy, and the relation between the incidence of ICT and ventricular dysfunction and dilatation.
PATIENTS AND METHODS
The present study retrospectively reviewed the files of 83 cases with DCMP who were followed between June 2004 and December 2011. The diagnosis of DCMP was based on the definitions and classification of the cardiomyopathies by the American Heart Association in 2006, as ventricular chamber enlargement and systolic dysfunction with normal LV wall thickness determined by two-dimensional transthoracic echocardiography (TTE). [9] Totally, five cases had ICT associated with DCMP. LV systolic function was measured using M-mode TTE and the Simpson method.
Causes of DCMP (viral analyses, screening for metabolic disease, carnitine level, endocrine-related causes, collagen vascular diseases, Kawasaki disease, abnormal origin of left coronary artery, atherosclerosis, structural heart diseases, renal diseases, dysrhythmia) were investigated in all groups. The thrombosis panel (homocysteine, antithrombin III, protein C and protein S levels, methylene tetrahydrofolate reductase, factor V Leiden, prothrombin 20210 gene mutation, factor levels, plasminogen levels), which was studied in the cases with ICT, was considered normal.
Statistical analyses were performed using PASW 17.0 (Statistical Package for the Social Sciences [SPSS], Chicago, IL). Data are described as frequencies, proportions, median with ranges, and means with SDs. For all tests, a p value ≤0.05 was considered statistically significant. Comparison of two groups was done using Mann-Whitney U-test. were diagnosed with DCMP were followed. The median age of the patients was 2.0 years (1 month-14.8 years). The cases were followed for a mean of 33.6±35.6 months (3 days-168 months). Thrombus was determined in four of the cases during follow-up; one of the patients was referred from another medical center with the diagnosis of cardiac thrombus. case received heparin for 6 days, whereas the third and fourth cases received heparin for 4 days and the treatment was maintained with warfarin. The thrombus completely resolved within 14 days in the second case, within 8 days in the third case and after 3 days in the fourth case. Warfarin was stopped after the 6th month and treatment was continued with acetylsalicylic acid at antiplatelet/antiaggregant doses. The fifth case, who had numerous ICT, had thromboembolism-related infarct areas in the lungs (Figs. 2a, b) and cerebellum (Fig. 3) . Primarily, recombinant tissue plasminogen activator (rt-PA) was given, and then the treatment was continued with low molecular weight heparin. The case died on the 2nd day of hospitalization due to respiratory failure resulting from pulmonary and cerebral thromboembolism.
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DISCUSSION
Many studies of thromboembolism and anticoagulation in patients with heart failure, including DCMP, have been performed in adult patients. ICT mostly occurs due to myocardial infarction in adults, whereas many factors can cause ICT in children. Stasis of blood flow due to LV systolic dysfunction and dilatation, dysrhythmia, intracardiac invasive procedures, and a hypercoagulable state can cause ICT. [2] [3] [4] [5] [6] 10, 11] DCMP-related thrombus is an important cause of morbidity and mortality among children. It is known that systemic thromboembolism risk is high in cases between the groups (p=0.910). Presence of groundglass opacity in both lungs of the first case ( Fig. 1) , who had ICT in the apical region of the LV, raised the possibility of the presence of a thrombus originating from the right side of the heart that was too small to be detected on TTE. However, the case died on the third day of treatment due to cardiopulmonary arrest. The second case had DCMP secondary to chronic renal failure. The case also had concomitant secundum atrial septal defect, moderate tricuspid insufficiency, and moderate pulmonary hypertension. The second with LV thrombus. The incidence of ICT in DCMP ranges from 4-16%, whereas it increases to 43-57% in pediatric autopsy reports. [10] [11] [12] [13] [14] [15] [16] [17] The risk for ICT and systemic thromboembolus increases in case of a LVEF <20%. [13, 14, 18, 19] Günthard et al. [13] detected ICT in 17 (14%) of 130 cases with DCMP. They found the left ventricle fractional shortening (LVFS) to be significantly lower in the cases with ICT (mean LVFS 10±3%) as compared to those without ICT (mean LVFS 17±6%). Falk et al. [14] detected thrombus in the LVs of 11 (44%) of 25 adults with non-ischemic DCMP. In comparison with the group without thrombus (LVFS 11-25%), they found the LVFS to be significantly low in these cases (LVFS ≤10%). McCrindle et al. [6] also found LVEF to be significantly low in DCMP cases with ICT (mean LVEF 21±9%) as compared to the other group (mean LVEF 28±15%). However, in line with the present study, Choi et al. [18] found no difference between the groups with and without thrombus in terms of LVEF.
Transthoracic echocardiogram (TTE) does not offer satisfactory views of the left atrial appendage. However, transesophageal echocardiography (TEE) is a reliable technique that gives a clear view of the left atrial appendage (LAA), with sensitivity and specificity of 100% and 99%, respectively. TEE was not suitable because most of our patients were infants. [20, 21] Patients with dilated LV and low EF seem to be at high risk for LV thrombus formation. In our study, although LVEDD was larger in the patients with ICTs, no statistically significant difference was found between the groups with and without ICT. Furthermore, LAA thrombosis should be considered when designing the treatment strategy for patients with DCMP at sinus rhythm. [20, 22] Whereas ICT is usually seen in the LVs of the cases with DCMP, it is mostly seen in the atria of the cases with pulmonary hypertension, Eisenmenger syndrome or atrial fibrillation. In case of severe systolic and diastolic dysfunction of the LV, thrombus is more likely to occur in the LV and left atrium due to stasis of blood flow, whereas it is more likely to occur in the right atrium in case of pulmonary hypertension. [6, 13, 18, [21] [22] [23] [24] However, the incidence of thrombus formation is decreased in LV dysfunction, since mitral insufficiency prevents stasis. [2, [25] [26] [27] [28] [29] [30] In the present study, mild mitral regurgitation was detected in the cases having ICT in the LV. The second case with ICT in the right atrium had moderate mitral insufficiency, secundum atrial septal defect and moderate pulmonary hypertension. We think that pulmonary hypertension might have contributed to the presence of the ICT in the right atrium.
There are different treatment options in DCMP patients with LV thrombus, like anticoagulation, antiplatelet therapy and surgery. Although it is difficult to recommend open-heart surgery to patients with a sole indication of LV thrombus, Lee et al. [31] stated in their study that systemic thromboembolism incidence is lower in patients treated with surgery when compared with other treatment options. It is known that anticoagulation therapy with warfarin reduces both the risk of ICT and subsequent thromboembolism. Guidelines recommend anticoagulation with warfarin for patients with ICT or cardioembolic stroke. [32, 33] Günthard et al. [13] recommended prophylactic anticoagulant therapy in DCMP cases with ICT if LVFS is <20%. Falk et al. [14] emphasized that the risk for ICT and thromboembolism was high in the cases not using anticoagulant and with low LVFS. Prophylactic antiplatelet, antiaggregant or anticoagulant therapy is recommended in the cases with LVEF <30%. [6, 13, 14, 19, 23] However, the present DCMP cases developed ICT and systemic thromboembolus even though their LVEFs ranged from 32-38%. It was clear that the cases with LVEF <30% who were receiving prophylactic antiaggregant therapy had no ICT. Therefore, it would be beneficial to review the criteria to commence prophylactic antiaggregant/antithrombotic therapy.
While prophylactic anticoagulants have been used in adults with DCMP to prevent ICT and systemic thromboembolus, [33] studies performed with children are limited. In recent years, thrombolytic agents such as rt-PA, streptokinase and urokinase have been used for ICT. [15, 34, 35] Although antiplatelet and antiaggregant agents are effective in preventing ICT, it is known that they have no effect on thrombus resolution. Heparin or oral anticoagulant should be used in the event of ICT. [13, 36] Nevertheless, there are authors that recommend prophylactic anticoagulant use when LVFS is decreased <20%. [6, 13, 23] The limitations of our study are its design as a single institution retrospective study, the underestimation of small thrombi with echocardiogram, and the inability to perform TEE in our patients, as most of them were infants.
